<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1786">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05137912</url>
  </required_header>
  <id_info>
    <org_study_id>e4c2e8edac362acab7123654b9e734</org_study_id>
    <nct_id>NCT05137912</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Immunotherapy in Advanced NSCLC</brief_title>
  <official_title>Neoadjuvant Immunotherapy in Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Power Life Sciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Power Life Sciences Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A number of clinical trials have demonstrated the efficacy of immunotherapy prior as&#xD;
      neoadjuvant therapy. This study evaluates whether said neoadjuvant immunotherapy may improve&#xD;
      improve progression free survival in NSCLC. One such example would be to evaluate either&#xD;
      single agent or an immunotherapy combination with chemotherapy. Following this, analysis of&#xD;
      biomarkers will be conducted to provide personalization in one's regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A number of clinical trials have demonstrated the efficacy of immunotherapy prior as&#xD;
      neoadjuvant therapy. This study evaluates whether said neoadjuvant immunotherapy may improve&#xD;
      improve progression free survival in NSCLC. [The Power Life Sciences Investigative&#xD;
      Team](https://www.withpower.com) is running a study to evaluate either single agent or an&#xD;
      immunotherapy combination with chemotherapy. Patients can contact a site administrator via&#xD;
      the information below, or enroll directly via &lt;a&#xD;
      href=&quot;https://www.withpower.com/trial/phase-4-2019-e67c1&quot;&gt;https://www.withpower.com/trial/pha&#xD;
      se-4-2019-e67c1&lt;/a&gt;. Following this, analysis of biomarkers will be conducted to provide&#xD;
      personalization in one's regimen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major Pathological Response</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To evaluate the major pathological response (MPR) rate of participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPR based on diverse PD-L1 expression</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Percentage of Participants with Major Pathologic Response Rates For Programmed Death Ligand 1 (PD-L1)-Positive Versus PD-L1-Negative Participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Progression Free Survival (PFS)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Lung Cancer, Non-small Cell</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunotherapy</intervention_name>
    <description>Patients within this intervention group will be histologically confirmed to have resectable non small cell lung cancer with stage II-IIIA.&#xD;
Patients may receive single agent immunotherapy or immunotherapy combined with chemotherapy.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Stage IIA-IIIA NSCLC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;= 18 Years of Age&#xD;
&#xD;
          -  Informed consent is provided&#xD;
&#xD;
          -  Histologically confirmed resectable non-small cell lung cancer with stage II-IIIA (TNM&#xD;
             8th edition)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  Epidermal growth factor receptor (EGFR) mutation negative and anaplastic lymphoma&#xD;
             kinase (ALK) translocation negative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  EGFR mutation positive and ALK translocation positive&#xD;
&#xD;
          -  Active central nervous system (CNS) metastases&#xD;
&#xD;
          -  Autoimmune diseases&#xD;
&#xD;
          -  Inhaled or topical steroids, and adrenal replacement steroid doses &gt; 10 mg daily&#xD;
             prednisone equivalent, are permitted in the absence of active autoimmune disease&#xD;
&#xD;
          -  Patients with interstitial lung disease will not be included if they have symptomatic&#xD;
             interstitial lung disease (ILD) - Grade 3-4&#xD;
&#xD;
          -  Women who are breast feeding or pregnant&#xD;
&#xD;
          -  Sexually active women or men of childbearing potential who are not willing to use an&#xD;
             effective contraceptive method during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Michael B Gill</last_name>
    <role>Study Director</role>
    <affiliation>[Power Life Sciences Inc.](www.withpower.com)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael B Gill</last_name>
    <phone>(415) 900-4227</phone>
    <email>bask@withpower.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patient Support</last_name>
    <email>hello@withpower.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Power Life Sciences</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael B Gill</last_name>
      <phone>415-900-4227</phone>
      <email>https://www.withpower.com/contact-us@withpower.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jiang L, Huang J, Jiang S, Rong W, Shen Y, Li C, Tian Y, Ning J, Chen X, Yang Y, Ding Z, Li Z, Luo Q. The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer. Cancer Immunol Immunother. 2021 Aug;70(8):2313-2321. doi: 10.1007/s00262-021-02847-1. Epub 2021 Jan 29.</citation>
    <PMID>33512555</PMID>
  </reference>
  <reference>
    <citation>Broderick SR. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer. Thorac Surg Clin. 2020 May;30(2):215-220. doi: 10.1016/j.thorsurg.2020.01.001. Review.</citation>
    <PMID>32327180</PMID>
  </reference>
  <reference>
    <citation>Gutierrez-Sainz L, Cruz-Castellanos P, Higuera O, de Castro-Carpe√±o J. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer. Curr Treat Options Oncol. 2021 Aug 23;22(10):91. doi: 10.1007/s11864-021-00885-6. Review.</citation>
    <PMID>34424417</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

